Evidence map›Paper›PMID 36032411›Full record

ArticleClinical, cosmetic and investigational dermatology2022

Luteolin is an Effective Component of

Liang Wang, Longjiao Hu, Zhilian Peng, Honghong Cao, Danfeng Cao, Yiqin Long, Zhengyu Zou

Abstract read
In one paragraph

Article in Clinical, cosmetic and investigational dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Polyphenols in wound healing: unlocking prospects with clinical applications.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Liang Wang *Pharmacy Department, Traditional Chinese Medicine Hospital of Jiulongpo Distriction Chongqing, Chongqing, People's Republic of China.
Longjiao Hu *Pharmacy Department, Chongqing Jiulongpo People's Hospital, Chongqing, People's Republic of China.
Zhilian PengAdministrative Department, Traditional Chinese Medicine Hospital of Jiulongpo Distriction Chongqing, Chongqing, People's Republic of China.
Honghong CaoPharmacy Department, Traditional Chinese Medicine Hospital of Jiulongpo Distriction Chongqing, Chongqing, People's Republic of China.
Danfeng CaoClinical Laboratory, Chongqing Jiulongpo People's Hospital, Chongqing, People's Republic of China.
Yiqin LongClinical Laboratory, Chongqing Jiulongpo People's Hospital, Chongqing, People's Republic of China.
Zhengyu ZouClinical Laboratory, Chongqing Jiulongpo People's Hospital, Chongqing, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: The protein expression levels of TNF-α and IL-6 were detected by ELISA. QRT-PCR was adopted to detect the expression of TGF-β1 and VEGF. Histopathological changes of scald wounds were analyzed by hematoxylin-eosin staining. Cell viability and migration ability were detected by CCK-8 assay and scratch assay. Results: Both in vivo and in vitro experiments showed that luteolin promoted wound healing of cutaneous scald injury. Gene Oncology (GO) functional analysis and rescue experiments showed that endothelial nitric oxide synthase 3 (NOS3) was the critical target of luteolin in treating cutaneous scald. Conclusion: This study demonstrated that luteolin is an effective component of

Indexed as

luteolinnetwork pharmacologynitric oxide synthasePlatycodon grandiflorusscald injury

Identifiers

PMID36032411
PMCPMC9400681

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.